Optimizing the Illumina COVIDSeq laboratorial and bioinformatics pipeline on thousands of samples for SARS-CoV-2 Variants of Concern tracking.
BAM, Binary Alignment Map
BED, Browser Extensible Data
Bioinformatics workflow
COVID mutations
FDA, Food and Drug Administration
HPC, High Performance Computing
Illumina COVID-seq
LIMS, Laboratory Information Management System
NGS, Next Generation Sequencing
Oncology
Oncology Metagenomics
RBD, Receptor-Binding Domain
SARS-CoV-2 Variants of Concern
SARS-CoV-2 genome
SARS-CoV-2 mutation
SARS-CoV-2, Severe Acute Respiratory Syndrome Coronavirus
TAT, Turnaround Time
VoC, Variants of Concern
Journal
Computational and structural biotechnology journal
ISSN: 2001-0370
Titre abrégé: Comput Struct Biotechnol J
Pays: Netherlands
ID NLM: 101585369
Informations de publication
Date de publication:
2022
2022
Historique:
received:
22
02
2022
revised:
06
05
2022
accepted:
16
05
2022
pubmed:
26
5
2022
medline:
26
5
2022
entrez:
25
5
2022
Statut:
ppublish
Résumé
The SARS-CoV-2 Variants of Concern tracking via Whole Genome Sequencing represents a pillar of public health measures for the containment of the pandemic. The ability to track down the lineage distribution on a local and global scale leads to a better understanding of immune escape and to adopting interventions to contain novel outbreaks. This scenario poses a challenge for NGS laboratories worldwide that are pressed to have both a faster turnaround time and a high-throughput processing of swabs for sequencing and analysis. In this study, we present an optimization of the Illumina COVID-seq protocol carried out on thousands of SARS-CoV-2 samples at the wet and dry level. We discuss the unique challenges related to processing hundreds of swabs per week such as the tradeoff between ultra-high sensitivity and negative contamination levels, cost efficiency and bioinformatics quality metrics.
Identifiants
pubmed: 35611117
doi: 10.1016/j.csbj.2022.05.033
pii: S2001-0370(22)00189-1
pmc: PMC9119164
doi:
Types de publication
Journal Article
Langues
eng
Pagination
2558-2563Informations de copyright
© 2022 The Author(s).
Déclaration de conflit d'intérêts
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Références
PLoS One. 2021 Feb 17;16(2):e0247115
pubmed: 33596239
China CDC Wkly. 2021 Dec 3;3(49):1049-1051
pubmed: 34934514
J Transl Med. 2020 Dec 30;18(1):494
pubmed: 33380328
Virus Evol. 2020 Oct 05;6(2):veaa075
pubmed: 33318859
JAMA. 2022 Feb 8;327(6):583-584
pubmed: 34967859
Nature. 2022 Feb;602(7895):19
pubmed: 35058630
Virus Evol. 2021 Jul 30;7(2):veab064
pubmed: 34527285
Nucleic Acids Res. 2021 Jul 2;49(W1):W619-W623
pubmed: 34048576
STAR Protoc. 2021 Sep 17;2(3):100755
pubmed: 34368787
Lancet. 2021 Dec 11;398(10317):2126-2128
pubmed: 34871545
Nat Microbiol. 2020 Nov;5(11):1403-1407
pubmed: 32669681